NASDAQ:STRO Sutro Biopharma (STRO) Stock Price, News & Analysis → A new way to collect income from stocks (From DTI) (Ad) Free STRO Stock Alerts $3.47 -0.25 (-6.72%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$3.40▼$3.7550-Day Range$3.27▼$5.6552-Week Range$2.01▼$6.13Volume540,902 shsAverage Volume1.27 million shsMarket Capitalization$216.67 millionP/E RatioN/ADividend YieldN/APrice Target$12.57 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Sutro Biopharma alerts: Email Address Sutro Biopharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside262.3% Upside$12.57 Price TargetShort InterestHealthy3.86% of Shares Sold ShortDividend StrengthN/ASustainability-0.70Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$60,925 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.18) to ($2.96) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.76 out of 5 starsMedical Sector53rd out of 907 stocksBiological Products, Except Diagnostic Industry7th out of 153 stocks 4.5 Analyst's Opinion Consensus RatingSutro Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSutro Biopharma has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.86% of the outstanding shares of Sutro Biopharma have been sold short.Short Interest Ratio / Days to CoverSutro Biopharma has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Sutro Biopharma has recently increased by 3.88%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldSutro Biopharma does not currently pay a dividend.Dividend GrowthSutro Biopharma does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSutro Biopharma has received a 73.67% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Preclinical research services for physical health" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Sutro Biopharma is -0.70. Previous Next 3.2 News and Social Media Coverage News SentimentSutro Biopharma has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.Search Interest11 people have searched for STRO on MarketBeat in the last 30 days. This is an increase of 1,000% compared to the previous 30 days.MarketBeat Follows5 people have added Sutro Biopharma to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sutro Biopharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $60,925.00 in company stock.Percentage Held by InsidersOnly 6.90% of the stock of Sutro Biopharma is held by insiders.Percentage Held by Institutions96.99% of the stock of Sutro Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Sutro Biopharma are expected to grow in the coming year, from ($3.18) to ($2.96) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sutro Biopharma is -1.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sutro Biopharma is -1.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSutro Biopharma has a P/B Ratio of 1.41. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressBiden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.See his shocking evidence in this new report About Sutro Biopharma Stock (NASDAQ:STRO)Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.Read More STRO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart STRO Stock News HeadlinesApril 17, 2024 | msn.comSutro Biopharma (STRO) Price Target Decreased by 6.45% to 13.15April 17, 2024 | americanbankingnews.comSutro Biopharma, Inc. (NASDAQ:STRO) Given Average Recommendation of "Buy" by AnalystsApril 25, 2024 | Insider Financial (Ad)Thousands of investors use this no cost solution | Do you? In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.April 3, 2024 | markets.businessinsider.comSutro Biopharma Buy Rating Justified by Strategic Partnerships and Promising PipelineApril 2, 2024 | finance.yahoo.comSutro Biopharma, Inc. (NASDAQ:STRO) Analysts Just Cut Their EPS Forecasts SubstantiallyApril 2, 2024 | markets.businessinsider.comIpsen Secures Exclusive Global Rights Of Sutro Biopharma's STRO-003 ADC In Up To $900 Mln DealApril 2, 2024 | msn.comIpsen secures exclusive global rights of Sutro Biopharma's STRO-003 ADCApril 2, 2024 | globenewswire.comSutro Biopharma Announces Pricing of $75 Million Underwritten OfferingApril 25, 2024 | Insider Financial (Ad)Thousands of investors use this no cost solution | Do you? In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.April 2, 2024 | marketwatch.comIpsen, Sutro Biopharma Enter Into Licensing Deal Valued at Up to $900 MlnApril 2, 2024 | globenewswire.comIpsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumorsApril 1, 2024 | msn.comPenny Stock Sutro Biopharma (NASDAQ:STRO): Intriguing Play for Biotech InvestorsMarch 27, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Sutro Biopharma (STRO), Catalyst Pharma (CPRX)March 27, 2024 | markets.businessinsider.comNavigating 4 Analyst Ratings For Sutro BiopharmaMarch 27, 2024 | finance.yahoo.comSutro Biopharma Inc (STRO) Earnings: A Mixed Bag Amidst Strategic AdvancesMarch 26, 2024 | finanznachrichten.deSutro Biopharma, Inc.: Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated MilestonesMarch 26, 2024 | markets.businessinsider.comTD Cowen Sticks to Its Buy Rating for Sutro Biopharma (STRO)March 26, 2024 | markets.businessinsider.comSutro Biopharma Buy Rating Affirmed on Strong Financials and Promising Clinical PipelineMarch 25, 2024 | investorplace.comSTRO Stock Earnings: Sutro Biopharma Beats EPS, Beats Revenue for Q4 2023March 25, 2024 | globenewswire.comSutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated MilestonesFebruary 10, 2024 | msn.comSutro Biopharma Expands Share Offering, Raises $129MJanuary 9, 2024 | markets.businessinsider.comSutro Biopharma: Hold Rating Maintained Amid Near-Term Uncertainties and Market Potential AmbiguitiesJanuary 6, 2024 | markets.businessinsider.comBuy Rating Justified: Sutro Biopharma’s Luvelta Shows Promise in PROC Treatment and BeyondJanuary 4, 2024 | finance.yahoo.comSutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADCDecember 29, 2023 | benzinga.comSutro Biopharma Stock (NASDAQ:STRO) Dividends: History, Yield and DatesDecember 18, 2023 | finance.yahoo.comSutro Biopharma, Inc.'s (NASDAQ:STRO) Share Price Boosted 48% But Its Business Prospects Need A Lift TooDecember 14, 2023 | finance.yahoo.comSutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024See More Headlines Receive STRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sutro Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/25/2024Today4/25/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:STRO CUSIPN/A CIK1382101 Webwww.sutrobio.com Phone(650) 392-8412FaxN/AEmployees302Year FoundedN/APrice Target and Rating Average Stock Price Target$12.57 High Stock Price Target$18.00 Low Stock Price Target$8.00 Potential Upside/Downside+262.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-106,790,000.00 Net Margins-69.47% Pretax Margin-57.63% Return on Equity-71.42% Return on Assets-24.92% Debt Debt-to-Equity RatioN/A Current Ratio4.50 Quick Ratio4.50 Sales & Book Value Annual Sales$153.73 million Price / Sales1.41 Cash FlowN/A Price / Cash FlowN/A Book Value$2.46 per share Price / Book1.41Miscellaneous Outstanding Shares62,440,000Free Float58,134,000Market Cap$216.67 million OptionableOptionable Beta0.95 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. William J. Newell J.D. (Age 66)CEO & Director Comp: $1.07MMs. Jane Chung R.Ph. (Age 52)President & COO Comp: $934.64kDr. James R. Swartz DScPh.D., Sc.D., FounderMr. Edward C. Albini M.B.A (Age 66)CFO & Secretary Comp: $596.4kDr. Venkatesh Srinivasan Ph.d.Chief Technical Operations OfficerDr. Hans-Peter Gerber Ph.D.Chief Scientific OfficerMr. David Pauling J.D.M.A., General CounselMs. Linda A. Fitzpatrick (Age 67)Chief People & Communications Officer Comp: $595.79kDr. Nicki Vasquez Ph.D. (Age 61)Chief Portfolio Strategy & Alliance Officer Dr. Anne Elizabeth Borgman-Hagey M.D. (Age 55)Chief Medical Officer More ExecutivesKey CompetitorsAdverum BiotechnologiesNASDAQ:ADVMCoherus BioSciencesNASDAQ:CHRSFennec PharmaceuticalsNASDAQ:FENCElevation OncologyNASDAQ:ELEVCompass TherapeuticsNASDAQ:CMPXView All CompetitorsInsiders & InstitutionsParkman Healthcare Partners LLCBought 20,263 shares on 2/15/2024Ownership: 1.973%Opaleye Management Inc.Bought 301,491 shares on 2/15/2024Ownership: 0.495%Kynam Capital Management LPBought 449,052 shares on 2/14/2024Ownership: 3.284%Sectoral Asset Management Inc.Bought 191,345 shares on 2/14/2024Ownership: 1.023%Tower Research Capital LLC TRC Sold 5,732 shares on 2/13/2024Ownership: 0.015%View All Insider TransactionsView All Institutional Transactions STRO Stock Analysis - Frequently Asked Questions Should I buy or sell Sutro Biopharma stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sutro Biopharma in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" STRO shares. View STRO analyst ratings or view top-rated stocks. What is Sutro Biopharma's stock price target for 2024? 7 analysts have issued 1-year target prices for Sutro Biopharma's stock. Their STRO share price targets range from $8.00 to $18.00. On average, they predict the company's share price to reach $12.57 in the next twelve months. This suggests a possible upside of 262.3% from the stock's current price. View analysts price targets for STRO or view top-rated stocks among Wall Street analysts. How have STRO shares performed in 2024? Sutro Biopharma's stock was trading at $4.29 at the beginning of 2024. Since then, STRO shares have decreased by 19.1% and is now trading at $3.47. View the best growth stocks for 2024 here. When is Sutro Biopharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our STRO earnings forecast. How were Sutro Biopharma's earnings last quarter? Sutro Biopharma, Inc. (NASDAQ:STRO) issued its quarterly earnings results on Monday, March, 25th. The company reported $0.42 EPS for the quarter, beating the consensus estimate of ($0.82) by $1.24. The company earned $113.72 million during the quarter, compared to analyst estimates of $12.16 million. Sutro Biopharma had a negative trailing twelve-month return on equity of 71.42% and a negative net margin of 69.47%. What ETFs hold Sutro Biopharma's stock? ETFs with the largest weight of Sutro Biopharma (NASDAQ:STRO) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR) and Loncar China Biopharma ETF (CHNA).Simplify Propel Opportunities ETF (SURI). What is William J. Newell's approval rating as Sutro Biopharma's CEO? 11 employees have rated Sutro Biopharma Chief Executive Officer William J. Newell on Glassdoor.com. William J. Newell has an approval rating of 100% among the company's employees. This puts William J. Newell in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Sutro Biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sutro Biopharma investors own include Pfizer (PFE), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Dynavax Technologies (DVAX), Fulcrum Therapeutics (FULC), IDEAYA Biosciences (IDYA), Provention Bio (PRVB), Sorrento Therapeutics (SRNE), Xeris Biopharma (XERS) and AbbVie (ABBV). When did Sutro Biopharma IPO? Sutro Biopharma (STRO) raised $75 million in an initial public offering (IPO) on Thursday, September 27th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Cowen and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. How do I buy shares of Sutro Biopharma? Shares of STRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:STRO) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe #1 Crypto for 2024InvestorPlaceFed launches fourth dollar overhaulStansberry ResearchGreat Crypto BullWeiss RatingsExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sutro Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
